ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer

ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer

ARID1A is an epigenetic regulator mutated in approximately 5% of non-hypermutated colorectal cancer tumors, however, its relationship with treatment response remains to be explored. Here, the authors suggest that ARID1A mutations may confer intrinsic and acquired resistance to cetuximab treatment.

Bibliographic Details
Main Authors: Radia M. Johnson, Xueping Qu, Chu-Fang Lin, Ling-Yuh Huw, Avinashnarayan Venkatanarayan, Ethan Sokol, Fang-Shu Ou, Nnamdi Ihuegbu, Oliver A. Zill, Omar Kabbarah, Lisa Wang, Richard Bourgon, Felipe de Sousa e Melo, Chris Bolen, Anneleen Daemen, Alan P. Venook, Federico Innocenti, Heinz-Josef Lenz, Carlos Bais
Format: Article
Language:English
Published: Nature Portfolio 2022-09-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-022-33172-5

Internet

https://doi.org/10.1038/s41467-022-33172-5

Similar Items